KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

Steven Knapper, Laura W Dillon, Malavika Babu, Abin Thomas, Ian Thomas, Christopher S Hourigan, Georgia Andrew, Richard Dillon, Amanda Gilkes, Nuria Marquez Almuina, Sophie King, Nicholas McCarthy, Reem Bahr, Rasha W Al-Ali, Louisa Stone, Tom Coats, Jennifer Byrne, Simone Green, Ulrik Malthe Overgaard, Rob S Sellar, Mike Dennis, Priyanka Mehta, Robert Hills, Sylvie D Freeman, Nigel H Russell

Blood 147(10) 1048-1057

PMID41237344
PMCIDPMC13052346
DOI10.1182/blood.2025031006
发表日期2025-11-14
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 1.:非 KM 图;Figure 2.:CONSORT/入组流程图;Figure 3.:非 KM 图;Figure 4.:森林图/亚组分析图;另有 1 张未列出。
摘要

摘要

We compared daunorubicin/cytarabine plus fractionated gemtuzumab ozogamicin (DAGO2) with CPX-351 (CPX; 1:2 randomization) in 439 patients with acute myeloid leukemia (AML) aged ≥60 years (median age, 68 years) without known adverse-risk cytogenetics. Median follow-up was 35 months. Patients not in measurable residual disease (MRD)-negative remission after course 1 could enter a second randomization between standard and intensified chemotherapy. Post-course 1, the overall response rate (complete remission [CR] + CR with incomplete hematological recovery) was greater after DAGO2 (60% vs 47.5%; odds ratio [OR], 0.61; P = .016). Following course 2, the overall response was not significantly different (85% for DAGO2 vs 78% for CPX; P = .095). More patients attained CR with MRD negativity after course 1 in the DAGO2 arm (47% vs 29% for CPX; OR, 0.46; P = .004). We observed better 3-year event-free survival (34% vs 27%; hazard ratio [HR], 0.73; P = .012) and overall survival (52% vs 35%; HR, 0.62; P = .001) with DAGO2. CPX did not provide a survival benefit in patients with myelodysplasia (MDS)-related mutations and was associated with poorer survival in patients with NPM1 (HR, 2.83) and FLT3 mutations (HR, 2.14). Overall, 37% of patients underwent transplantation in first remission, with no difference in transplantation frequency or survival after transplant between randomization groups. Among patients entering the course 2 randomization (n = 107), survival was equivalent between standard and intensified CPX doses (P = .565). In conclusion, in this population of older patients with AML without known adverse-risk cytogenetics, DAGO2 resulted in superior survival compared with CPX. CPX did not benefit patients with MDS-related mutations over DAGO2. This trial was registered at www.ClinicalTrials.gov as #NCT02272478.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Figure 1.Trial schema. CPX total doses (units per square meter) by course are given in brackets (further information in “Methods”). Post–course 1 randomization in DAGO arm for patients with residual or unassessable disease is reported by Russell et al 4 (further information on FLAG-Ida schedule is provided in “Methods”). CR, complete remission; DA, daunorubicin/AraC; GO2, gemtuzumab ozogamicin, 2 doses; FLAG-Ida, fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin; MRD, measurable residual disease; R, randomization.
非 KM Figure
Figure 2.CONSORT diagram.
非 KM Figure
Figure 3.Survival outcomes by randomization. (A) EFS. (B) OS.
非 KM Figure
Figure 4.Subgroup analysis of OS. (A) Patient characteristics. (B) Baseline genetics. MDS-related mutation subgroup includes patients with NPM1 or FLT3-ITD/TKD mutations. ECOG, Eastern Cooperative Oncology Group; ELN, European LeukemiaNet; O-E, observed to expected; Var., variance; WBC, white blood cells.
非 KM Figure
Figure 5.Forest plot of OS by randomization for patient subgroup with MDS-related mutations, excluding NPM1 or FLT3-ITD/TKD mutations, vs others. O-E, observed to expected; Var., variance.
非 KM Figure